Payment overview · 2025
General Payments
$756.71
44 reported records · 18 companies
Healthcare provider profile · identity verified
William Ford Threlkeld, MD
Allopathic & Osteopathic Physicians|Family Medicine · WILLIAMSTOWN, KY · NPI 1205893112
Verified facts
What the public records show
CMS Open Payments records show William Ford Threlkeld, MD received $756.71 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $186.35 | 24.6% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $76.94 | 10.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.22 | 9.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.86 | 7.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.80 | 5.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.48 | 5.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.18 | 5.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.51 | 4.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.08 | 4.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.80 | 4.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.55 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.69 | 3.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.86 | 2.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.59 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.57 | 2.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.07 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.87 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.29 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $756.71 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.75 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.11 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.36 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $76.94 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $55.74 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.80 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.62 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 76 |
| Omeprazole | Omeprazole | 198 | 65 |
| Benazepril Hcl | Benazepril Hcl | 196 | 62 |
| Metformin Hcl | Metformin Hcl | 184 | 51 |
| Lisinopril | Lisinopril | 177 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 57 |
| Cefdinir | Cefdinir | 136 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 43 |
| Prednisone | Prednisone | 101 | 76 |
| Furosemide | Furosemide | 98 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 43 |
| Sertraline Hcl | Sertraline Hcl | 94 | 30 |
| Losartan Potassium | Losartan Potassium | 91 | 28 |
| Gabapentin | Gabapentin | 86 | 27 |
| Allopurinol | Allopurinol | 84 | 29 |
| Trazodone Hcl | Trazodone Hcl | 84 | 22 |
| Meloxicam | Meloxicam | 83 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 27 |
| Eliquis | Apixaban | 77 | 22 |
| Farxiga | Dapagliflozin Propanediol | 77 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 76 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 23 |
| Potassium Chloride | Potassium Chloride | 74 | 26 |
| Alendronate Sodium | Alendronate Sodium | 67 | 19 |
| Buspirone Hcl | Buspirone Hcl | 64 | 29 |
| Baclofen | Baclofen | 57 | 19 |
| Ezetimibe | Ezetimibe | 57 | 23 |
| Mounjaro | Tirzepatide | 57 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 29 |
| Jardiance | Empagliflozin | 56 | 20 |
| Metformin Hcl Er | Metformin Hcl | 56 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 14 |
| Carvedilol | Carvedilol | 52 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Ozempic | Semaglutide | 51 | 17 |
| Montelukast Sodium | Montelukast Sodium | 50 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Valsartan | Valsartan | 43 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 30 |
| Levofloxacin | Levofloxacin | 38 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 13 |
| Glimepiride | Glimepiride | 37 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 13 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | 11 |
| Famotidine | Famotidine | 26 | 11 |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Ondansetron Odt | Ondansetron | 24 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | 11 |
| Valacyclovir | Valacyclovir Hcl | 23 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Topiramate | Topiramate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | 11 |
| Airsupra | Albuterol Sulfate/Budesonide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $756.71 · 44 records | ABBVIE INC. | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, GEMTESA, HETLIOZ, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error